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Abstract
Background: New, more sensitive and specific biomarkers are needed to support other means
of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in
discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/
serum, including that there is no one proteomic platform that can offer complete identification of
differences in proteomic profiles. Another set of problems is associated with heterogeneity of
human samples in addition intrinsic variability associated with every step of proteomic investigation.
Validation is the very last step of proteomic investigation and it is very often difficult to validate
potential biomarker with desired sensitivity and specificity. Even though it may be possible to
validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic
biomarker.
Results: In the current study we report results of proteomic analysis of sera from HIV-infected
individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by
weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of
gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort
of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel
Electrophoresis technology.
Conclusion: Validation using western-blot analysis led us to conclude that relative change of the
levels of these proteins in one patient during a timeframe might be more informative, sensitive and
specific than application of average level estimated based on an even larger cohort of patients.
Background
HIV-1 penetrates the brain shortly after infection and
remains there throughout entire disease. Approximately
50% of infected individuals develop some form of cogni-
tive impairment ranging from an asymptomatic form
diagnosed during formal testing to the most severe HIV-
associated dementia (HAD) leading to death [1].
Although antiretroviral therapy (ART) has a profound
effect on slowing disease progression, increasing survival
and decreasing the number of HAD incidents from 30 to
7%, the rate of HIV-1 infected patients with HIV-associ-
ated Neurocognitive Disorders (HAND) remains the same
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[1,2]. In consequence, the prevalence of HAD has
increased due to increased survival of these individuals [3-
7]. These epidemiological data suggest that ART provides
only partial protection against neurological damage in
HIV-infected people [8].
Despite of more than 20 years of research efforts we are
lacking good biomarkers supporting diagnosis of HAND
including its most severe form, HAD [9,10]. Current diag-
nosis and identification of HAND is based on neuropsy-
chological tests and exclusion of other potential causes
such as opportunistic infections, tumor etc [11]. Labora-
tory tests of disease progression, although valuable, are
not diagnostic and pose a need for more accurate and reli-
able markers to monitor progression of cognitive impair-
ment [12-14]. Good and reliable diagnostic biomarkers
are also indispensible for development of new therapeutic
strategies. Discovery of biomarkers, which could be used
to predict dementia and monitor disease progression, is
important for the development of early and effective treat-
ments designed to maintain normal cognition and quality
of life [15,16].
Despite the technological progress in recent years in sam-
ple preparation for proteomic analyses, fractionation
techniques and increased sensitivity of mass spectrome-
ters, proteomic analysis of serum/plasma and cerebrospi-
nal fluid (CSF) poses significant challenges [17-21]. High
complexity and high dynamic range of proteins and pep-
tides circulating in plasma and low levels of proteins orig-
inating from tissue leakage are just few of the most
important challenges [22,23]. Immunodepletion of most
abundant proteins from plasma/serum and CSF samples
is the most common first step in reducing complexity of
these samples. Although such approach has proven to be
useful, further steps of sample fractionation are desirable
[24].
Global proteomic profiling of clinical samples brought
high expectations for accelerated discovery of new
biomarkers to aid physicians in diagnosing and research-
ers in understanding molecular mechanisms of diseases.
However, high dynamic range of plasma/serum and CSF
proteins created challenges in such analyses. Immunode-
pletion became a standard first step, yet there is no con-
sensus to how many of the most abundant proteins need
to be removed. We have used IgY based technology for
immunodepletion of CSF and sera samples in our previ-
ous studies [25,26]. Another challenge is the choice of a
single or combination of profiling technology platforms.
In our previous studies we used 2-dimensional electro-
phoresis (2DE) with Differential Gel Electrophoresis
(DIGE) profiling method of immunodepleted CSF or sera
from HIV-1 infected individuals with or without HAD
[25,27] and demonstrated several differentially expressed
proteins which can be potential biomarkers.
Although CSF surrounding the brain and spinal cord
seems to be the best clinical material to reflect ongoing
pathological processes [28-32], evaluations of the CSF
proteome pose a challenge of availability of sufficient
amount of protein in addition to high dynamic range of
proteins. Alternatively, plasma or serum samples can be
used. However, the question that remains is how closely
changes in proteome profile of blood proteins reflect
changes in the brain which is behind blood brain barrier
(BBB). Because BBB is compromised during HIV infec-
tion, we posit that proteins from CSF leak into the blood
and can be detected as biomarkers. In addition we expect
that the plasma/serum proteome can be reflective of
increased neuroinflammation. Although such surrogate
biomarkers are not exclusive for HIV infection, they can
be relevant and helpful as auxiliary tests [33].
Our current work indicates that multiple protein profiling
approaches as well as multiple sample fractionation
schemes are required to more completely assess changes
in proteomes due to pathological changes [34]. Our data
also indicates that biomarker levels should be measured
relative to baseline for any individual to assess relative
changes rather than comparing to a set threshold.
Although putative biomarkers discovered during this
study are unlikely to be stand alone measures of disease or
suspected disease, they can be part of a broader diagnostic
approach including psychological and brain imaging tests
[35,36].
Results and discussion
Proteomic profiling
Serum samples used in this study were provided by Neu-
roAIDS Tissue Consortium and were obtained from HIV-
1 infected individuals with or without HAD. Although
introduction of ART resulted in significant decrease of
HAD cases [1], we decided to use samples representing
opposite spectrum of the disease to maximize chance in
discovering biomarkers of an ongoing neurodegenerative
process. Samples were immunodepleted from 12 most
abundant proteins prior to proteomics profiling. For this
purpose we used immunoaffinity chromatography with a
column that is based on IgY technology [25,26]. In our
previous proteomic investigation of this set of sera sam-
ples we used 2DE DIGE as profiling method and found
three differentially expressed proteins: complement C3,
ceruloplasmin and afamin [26]. Differential expression of
two of them, ceruloplasmin and afamin, was further vali-
dated by western blot analysis [26].
In this study we used SELDI-TOF ProteinChip® assays to
profile proteomes of the same immunodepleted serum
samples as in previous published study. We hypothesized
that by applying different profiling approach we will dis-
cover differentially expressed proteins which were not
found using 2DE DIGE. We choose SELDI-TOF profilingProteome Science 2009, 7:8 http://www.proteomesci.com/content/7/1/8
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because of two reasons. One was to investigate proteins
and/or their processed forms in low (~4 kDa) to medium
low (~28 kDa) range of molecular weight for which 2DE
DIGE is not an optimal profiling method. Our second rea-
son for using SELDI-TOF ProteinChip® technology was an
ability of direct translation of chromatographic condi-
tions from analytical to preparative mode as indicated as
steps 3 and 4 in Figure 1. We have previously used this
approach for identification of differentially expressed pro-
teins [37]. Acquired SELDI-TOF spectra were subjected to
rigorous statistical analysis and resulted in the identifica-
tion of 50 peaks which potentially represent differentially
expressed proteins. Among those 50 peaks detected, 21
showed statistically significant differences in intensities (p
< 0.05) (Additional file 1, Table S1), however only 4
showed high significance, as illustrated in Table 1. Two
peaks with m/z 4,493 and 25,872 showed increased
intensity associated with HAD and 2 other peaks showed
opposite trend (Table 1). Considering the highly variable
nature of SELDI-TOF spectra we approached interpreta-
tion of such spectra with caution, therefore, some differ-
ences showing borderline significance may not be
confirmed when larger number of spectra is generated.
Weak Cation Exchange (WCX) chromatography and 1DE
First dimension fractionation was immunodepletion of
12 most abundant proteins using IgY12 immunoaffinty
chromatography. Therefore, preparative WCX chromatog-
raphy was the second dimension fractionation reflecting
conditions used in SELDI-TOF profiling. At the same time
it allowed us to obtain amounts of protein sufficient for
one more step of sample fractionation and mass spec-
trometry based protein identification. Despite of two
steps of fractionation, samples were still complex enough
to compromise detection of differentially expressed pro-
teins. Therefore, we used 1DE in the subsequent step.
Because we were specifically interested in low molecular
weight proteins we used 16% Tricine gel and developed
protein resolution only to the half of a distance. This
approach allowed us to separate proteins in the region
from 4 to 28 kDa while maintaining undiffused protein
bands (Figure 2A, boxes 1 to 8). As expected we observed
differences in intensities of protein bands based on stain-
ing with SyproRuby reflecting differences in relative abun-
dance of proteins. The most profound difference was
observed in band 3 (Figure 2) and as illustrated in Figure
2 we excised corresponding gel cubes which were further
subjected to trypsin digestion and subsequent protein
identification based on nano-LC-MS/MS analysis. Table 2
summarizes identified proteins (corresponds to Figure
2A).
The most profound difference observed in band 3 of Fig-
ure 2A was also reflected by the degree of sequence pro-
tein coverage of identified prealbumin (NCBI accession#
BAA00059) which is now called transthyretin. The only
difference in amino acid sequence of 147 a.a. long
polypeptide chain of prealbumin and 148 a.a. long tran-
sthyretin (NCBI accession# AAP36542) is one additional
Leu as C-terminal residue in the latter protein. Electro-
phoretic migration of this protein corresponds well with
its theoretical molecular weight of prealbumin 15,919 Da
as well as transthyretin 16,032 Da (Figure 2A).
In the subsequent experiment we used 4–12% Bis-Tris gel
to separate proteins in the high molecular weight region
(Figure 2B). We did not investigate proteins of this size
using SELDI-TOF profiling. Our previous experience with
this technology platform showed that while in a complex
mixture very few proteins above 50,000 m/z mark can be
detected using our criteria of the first and second pass.
Such proteins were usually detected as broad peaks with
low intensity and relatively high difference between theo-
retical and experimentally measured masses. Neverthe-
less, we predicted that the applied scheme of fractionation
and profiling will result in uncovering differential
expressed proteins in high molecular weight range.
Results of 1DE analysis are shown in Table 3 (corresponds
to Figure 2B). We observed one protein band which
showed clear difference in abundance and was higher in
HAD. Subsequent LC-MS/MS analysis of tryptic digest
resulted in identification of gelsolin (Accession#
gi|121116|sp|P06396.1|GELS_HUMAN [121116]).
Western blot validation
Validation of putative biomarkers resulting from pro-
teomic analyses poses a significant challenge. One of the
reasons is high diversity in the levels of proteins within
normal human population. For example, in CSF concen-
tration of gelsolin ranges from 1.2 to 15.9 μg/ml [38].
Among validation methods available at this time we have
chosen western blot analysis [25,26]. This experimental
Table 1: SELDI-TOF protein peaks in HIV-affected individuals 
with HAD compared to without HAD
Peak Number Peak
Median
m/z
P-value1 Peak Intensity 2
1 4,493 0.000368 Increased
2 6,435 0.000196 Decreased
3 6,633 7.80E-05 Decreased
4 25,872 3.79E-06 Increased
1) P value ≤ 0.001 (i.e., 0.05/50), the adjusted criteria after Bonferroni 
correction for multiple testing). 2) Peak intensity of HIV-affected 
individuals with HAD as compared to without HAD.Proteome Science 2009, 7:8 http://www.proteomesci.com/content/7/1/8
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Experimental design Figure 1
Experimental design. Flow chart presenting experimental design of proteomic analysis combining immunodepletion, SELDI-
TOF, ion exchange chromatography, 1D SDS-PAGE and LC MS/MS.
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Table 2: Identifications of proteins in eight gel sections shown in Figure 2A
Band # Protein Name MW Swiss Prot NCBI Peptides
ND HAD
2 pro-platelet basic protein precursor 13894.1 4505981 2 0
2 unnamed protein product 66019.2 B2RA01 189054178 2 2
3 prealbumin 15919.0 P02766 219978 5 0
3 unnamed protein product 66019.2 B2RA01 189054178 2 0
4 unnamed protein product 66019.2 B2RA01 189054178 2 0
4 prealbumin 15919.0 P02766 219978 2 2
4 TETN_HUMAN Tetranectin precursor 22566.7 P05452 267108 3 2
4 Complement component C8 gamma chain 22219.3 P07360 29577 0 2
5 A Chain A, Crystal Structure Of Human Apolipoprotein A-I 23403.4 2914175 0 2
5 apolipoprotein A-I preproprotein 30777.6 4557321 0 2
5 TETN_HUMAN Tetranectin precursor 22566.7 P05452 267108 0 2
5 L Chain L, Crystal Structure Of Tissue Factor In Complex With Humanized Fab 
D3h44
23499.0 18655500 0 2
6 mannose-binding lectin 26090.3 P11226 5911809 2 2
6 inter-alpha-trypsin inhibitor family heavy chain-related protein 103384.8 Q14624 1483187 2 2
6 apolipoprotein A-I preproprotein 30777.6 4557321 0 2
6 A Chain A, Crystal Structure Of Human Apolipoprotein A-I 23403.4 2914175 0 2
6 L Chain L, Crystal Structure Of Tissue Factor In Complex With Humanized Fab 
D3h44
23499.0 18655500 0 2
7 inter-alpha-trypsin inhibitor family heavy chain-related protein 103384.8 Q14624 1483187 3 3
7 complement factor I preproprotein 65720.0 119392081 3 0
7 mannose-binding lectin 26090.3 P11226 5911809 2 2
7 B Chain B, Human Complement Component C3 112940.1 78101268 4 0Proteome Science 2009, 7:8 http://www.proteomesci.com/content/7/1/8
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approach is convenient because of relative high through-
put and widely available software for quantitative analy-
sis. Another advantage is small amount material required
for such analysis which is important when quantity of
sample is limited. Although usually serum/plasma is one
of the most abundant clinical materials available for pro-
teomic analysis, total pool of proteins obtained after
immunodepletion of 12 most abundant proteins contains
approximately 4–5% of the initial amount [22]. In this
step, we used western blot combined with quantitative
densitometry measurements of resulting bands to analyze
levels of gelsolin in all 14 samples individually. Results
presented in Figure 3 show a trend in increased expression
of gelsolin in sera samples of patients with HAD; however,
no statistically significant difference has been found
between these two populations of samples. Lack of signif-
icant difference can be attributed to small sample number
and the presence of outliers. We further hypothesize that
because baseline level of gelsolin within normal human
population is substantially variable, less profound
changes due to pathological conditions when averaged
may not yield statistical significance. Therefore, change
observed for any given patient over time might be much
more informative. This, however, needs to be investigated
in a longitudinal study using samples from three groups
of patients: one, those who showed signs of progression
of cognitive impairment, two, those who showed signs of
no change and three, and those who showed signs of
improvement.
Conclusion
It has been previously shown that one proteomic platform
and/or profiling approach does not uncover all existing
differences which can be valuable biomarker candidates
[24,39-41]. This is also true for current investigation.
Therefore, in this report we present continuation of our
previously published profiling of sera from HIV-1 infected
individuals with or without CI [26]. We used the same
cohort of samples, however, different profiling approach
and now found that gelsolin and prealbumin were differ-
entially expressed. Previous approach using 2DE DIGE
did not show differences in expression of these two pro-
teins. This could be attributed to the fact that both pro-
teins were located in high and low regions of gels used in
2DE, where resolution of spot is less favorable. Validation
of our data using western-blot analysis did not reach sta-
tistical significance difference between average values
because of high variability of expression of these two pro-
teins within population. There were also few samples
which we classified as outliers. If these samples are
removed from analysis, statistical significance can be
achieved. It has to be noted that the only criterion for sam-
ple classification was clinical diagnosis of HAD or lack of
it. The far high or far low levels of proteins (biomarkers)
might be attributed to other factors such as opportunistic
infections etc. Nevertheless, addition of gelsolin as a
biomarker candidate to ceruloplasmin and afamin as pre-
viously reported by us [26], reinforced our classification
of HAD and non-HAD samples. Figure 4 represents com-
7 clusterin isoform 2 52494.3 42740907 2 0
8 complement factor I preproprotein 65720.0 119392081 0 3
8 clusterin isoform 2 52494.3 42740907 0 2
8 inter-alpha-trypsin inhibitor family heavy chain-related protein 103384.8 Q14624 1483187 0 2
Table 2: Identifications of proteins in eight gel sections shown in Figure 2A (Continued)
1D Electrophoresis Figure 2
1D Electrophoresis. 1D SDS-PAGE. ND and HAD pooled 
samples were first depleted from 12 most abundant proteins, 
then processed through a weak cation exchange column, 
then 20 ug of each sample was loaded on 16% tricine gel and 
stained with sypro ruby. Numbers on the right-hand side of 
gels indicate band number that corresponds to Table 2 and 3, 
respectively. ND-non-demented; HAD-demented.
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Table 3: Identifications of proteins in three gel sections shown in Figure 2B
Band # Protein Name MW Swiss Prot NCBI Peptides
ND HAD
1 vitamin D-binding protein/group specific component 52950.4 P02774 455970 3 5
1 CO4A_HUMAN Complement C4-A precursor (Acidic complement C4) 192769.5 P0C0L4 81175238 2 2
1 complement factor B preproprotein 85532.4 P00751 67782358 3 5
1 afamin precursor 69068.8 P43652 4501987 3 2
1 inter-alpha (globulin) inhibitor H1 101401.4 4504781 7 4
1 complement component 1 inhibitor precursor 55153.9 P05155 73858568 1 2
1 attractin isoform 1 158535.6 O75882 21450861 2 1
1 complement factor H 51033.7 P08603 758073 1 1
1 factor H 139124.7 31965 1
1 alpha 1B-glycoprotein 54253.2 Q68CK0 21071030 1 2
1 Complement component 6 precursor 104843.6 P13671 4559406 2 3
1 ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy c 106435.6 P19823 125000 2 2
1 A Chain A, Complex Of The Catalytic Domain Of Human Plasmin And 
Streptokinase
27286.2 5821850 1 3
1 serpin peptidase inhibitor, clade A, member 3 precursor [Homo sapiens] 47650.6 50659080 1 2
1 gelsolin isoform a precursor 85696.9 P06396 4504165 0 3
1 A2MG_HUMAN Alpha-2-macroglobulin precursor (Alpha-2-M) 163276.5 P01023 112911 7 0
2 proceruloplasmin 108339.1 P00450 219549 1 1
2 hemopexin 51676.1 P02790 11321561 2 2
2 afamin precursor 69068.8 P43652 4501987 2 2
2 vitamin D-binding protein/group specific component 52950.4 P02774 455970 2 7
2 CO4A_HUMAN Complement C4-A precursor (Acidic complement C4) [Contains: 
Comple
192769.5 P0C0L4 81175238 2 2
2 gelsolin isoform a precursor 85696.9 P06396 4504165 0 2
2 complement factor B preproprotein 85532.4 P00751 67782358 3 4
2 serpin peptidase inhibitor, clade A, member 3 precursor 47650.6 50659080 3 3
2 alpha 1B-glycoprotein 54253.2 Q68CK0 21071030 4 3Proteome Science 2009, 7:8 http://www.proteomesci.com/content/7/1/8
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bined results from previous [26] and current study.
Another conclusion that we can make based on this study
is that for future experiments cohorts of samples need to
be assembled based on very careful clinical diagnosis of
patients to eliminate variation introduced by other con-
current pathologies, e.g. HCV. This, in turn may reduce
variability within the groups.
Summarizing, our main conclusion from this study is that
because of high diversity of expression of some proteins
among individuals, the relative change over time intervals
such as treatment for any given patient might serve as
more useful biomarker to aid other means of diagnosis of
cognitive impairment than calculated average levels
among large cohorts which will not generate statistically
significant differences. HAND is a relatively slowly pro-
gressing disease therefore changes measured in weeks or
even months intervals can still be useful as aid in diagnos-
tics.
Methods
For this study, we used 14 sera samples from HIV-1
infected individuals with (HAD) or without (ND) HIV-1-
associated dementia (7 from each group). Samples were
2 antithrombin III variant 52691.3 Q7KZ97 576554 2 3
2 complement component 1 inhibitor precursor 55153.9 P05155 73858568 2 3
2 ceruloplasmin precursor 122204.3 P00450 4557485 3 3
2 Complement component 6 precursor 104843.6 P13671 4559406 2 3
2 A Chain A, Complex Of The Catalytic Domain Of Human Plasmin And 
Streptokinase
27286.2 5821850 2 3
2 inter-alpha (globulin) inhibitor H1 101401.4 4504781 2 1
2 alpha-2-HS-glycoprotein 39324.4 4502005 1 2
3 CO4A_HUMAN Complement C4-A precursor (Acidic complement C4) [Contains: 
Comple
192769.5 P0C0L4 81175238 1 2
3 hemopexin 51676.1 P02790 11321561 2 2
3 complement factor B preproprotein 85532.4 P00751 67782358 1 6
3 vitamin D-binding protein/group specific component 52950.4 P02774 455970 5 7
3 Complement component 6 precursor 104843.6 P13671 4559406 4 4
3 complement component 2 precursor 83267.4 P06681 14550407 0 2
3 inter-alpha (globulin) inhibitor H1 101401.4 4504781 2 2
3 A Chain A, Complex Of The Catalytic Domain Of Human Plasmin And 
Streptokinase
27286.2 5821850 1 3
3 antithrombin III variant 52691.3 Q7KZ97 576554 1 2
3 complement component 1 inhibitor precursor 55153.9 P05155 73858568 4 3
3 plasminogen 90568.6 P00747 4505881 0 2
3 alpha-1-microglobulin; bikunin 16541.7 579676 1 2
Table 3: Identifications of proteins in three gel sections shown in Figure 2B (Continued)Proteome Science 2009, 7:8 http://www.proteomesci.com/content/7/1/8
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previously obtained from the National NeuroAIDS Tissue
Consortium (NNTC, https://www.nntc.org/) under
Request# R101. Use of sera samples in this study has been
approved by UNMC Institutional Review Board (#196-
05-EX).
IgY PARTITIONING (IMMUNODEPLETION)
We used the ProteomeLab IgY-12 High Capacity Pro-
teome Partitioning Kit (Beckman Coulter, Fullerton, CA)
to remove the 12 most abundant serum proteins, includ-
ing albumin, fibrinogen, transferrin, haptoglobin, IgG,
IgA, IgM, apo A-I and II, α1-antitrypsin, α1-acid glycopro-
tein and α2-macroglobulin. The kit included a HPLC
affinity column LC10 (12.7 × 79.0 mm) with a capacity of
0.25 mL of human serum per cycle and optimized buffers
for sample loading, washing, eluting and regenerating.
Serum samples were centrifuged at 18,000 × g for 15 min
at 4°C to pre-clear and delipidate samples prior to chro-
matography. The middle layer of pre-cleared serum was
collected, diluted (0.25 mL of serum and 0.375 ml of dilu-
tion buffer, 10 mM Tris-HCL pH 7.4, 0.15 M NaCl) and
filtered through 0.45 μm spin filters. Diluted samples
(0.625 mL) were loaded at flow rate 0.5 mL/minute and
flow-through fractions were collected and then concen-
trated using Amicon Ultra-15 centrifugal filters (Milli-
pore, Billerica, MA). Eluted fractions were then obtained
with 0.1 M glycine-HCL pH 2.5, neutralized with 0.1 M
Tris-HCl pH 8.0, equilibrated with 10 mM Tris-HCL pH
7.4, 0.15 M NaCl at a flow rate 2 mL/min and saved for
further studies.
SELDI-TOF
Protein signatures of individual sera samples were per-
formed by SELDI-TOF ProteinChip® assays (Bio-Rad, Her-
cules, CA). The chip type selection (WCX2) and washing
conditions were previously optimized [37]. Briefly, each
chip was pretreated with 10 mM HCl, rinsed with HPLC
grade water, then equilibrated with binding buffer (100
mM ammonium acetate, pH 4.0, with 0.1% Triton X-
100). Each sample was diluted in binding buffer at a con-
centration of 0.02 ug/uL, with a total of 1 ug applied to
each spot and incubated at room temperature for 30 min
while shaking. Unbound proteins were removed by wash-
ing spots twice with binding buffer followed by washing
with HPLC grade water. After drying each spot, 50%
sinapinic acid (SPA) matrix was added to each spot, air-
dried, then reapplied. SPA was prepared as a saturated
solution containing 30% acetonitrile (ACN), 15% isopro-
panol, 0.5% trifluoroacetic acid (TFA) and 0.05% Triton
X-100. The ionized proteins and their molecular mass/
charge (m/z) ratios were detected using SELDI-TOF. The
Western blot Figure 3
Western blot. Levels of gelsolin in sera samples from HIV 
infected patients with or without dementia. Arbitrary units 
are based on quantitative Western blot analysis. ND-non-
demented; HAD-demented.
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Sample classification Figure 4
Sample classification. Classification of ND and HAD sam-
ples based on levels of afamin, ceruloplasmin and gelsolin as 
determined by densitometry measurements of Western blot 
films. ND-non-demented; HAD-demented.
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mass spectra were collected using a PBS II ProteinChip®
Biosystems and analyzed with ProteinChip®  software
3.2.1 (both from BioRad). The ProteinChip® analysis was
performed in triplicate. The ProteinChip® reader was exter-
nally calibrated for each analysis using the four standard
proteins: bovine insulin (5,733.6 Da), cytochrome C
(12,230.9 Da), superoxide dismutase (SOD) (15,5941.4
Da), and β-lactoglobulin (18,636.3 Da). Peaks were auto-
matically detected using Biomarker Wizard of Protein-
Chip® software 3.2.1 with the following parameters: first-
pass signal/noise (S/N) ratio = 5, second-pass S/N ratio =
2, and mass tolerance = 0.5%; estimated peaks were
included in completion of clustering.
HPLC (second dimension fractionation)
HPLC protein fractionation was performed using a liquid
chromatography system (Shimadzu, Columbia, MD),
which included a pump, system controller, manual injec-
tor with 500 uL injection loop, ultraviolet-visual (UV-Vis)
detector set at 220 nm and fraction collector. The system
was controlled using a Dell computer and EZStart chro-
matographic software (Shimadzu). The mobile phase
consisted of mobile phase A (0.1 M ammonium acetate,
pH 4.0) and mobile phase B (0.1 M ammonium acetate +
0.5 M NaCl, pH 4.0). A weak cation exchange column
(100 × 2.1 mm; Eprogen, Darien, IL) was used for chro-
matographic separations of sera samples. The flow rate
was set at 0.200 mL/min. Before sample injection, the col-
umn was pretreated with 10 mM HCl for 20 min and
equilibrated with mobile phase A for 15 min. After sample
injection, mobile phase A was continued for 30 min, then
switched to mobile phase B for 30 min to 60 min. A total
of 300 ug of each group (ND or HAD) in mobile phase A
was injected into the column at time 0 min. Under these
chromatographic conditions, bound proteins were eluted
from the column between 40–45 min.
1-Dimensional Electrophoresis (1DE) (third dimension 
fractionation) and In Gel Tryptic Digest
WCX-HPLC fractions were mixed with NuPAGE®  LDS
sample buffer (Invitrogen) and separated by 1DE. For this
study, 30 ug of each fraction was loaded into each well of
a NuPAGE® Novex 12% Bis-Tris gel (Invitrogen) under
reducing conditions using MES running buffer. Twenty
micrograms of the WCX-HPLC fractions were vortexed in
Novex® Tricine SDS sample buffer (Invitrogen), loaded on
to a 16% Novex® gel and ran under reducing conditions
using Tricine SDS running buffer. After electrophoresis,
the above gels were stained with Sypro Ruby, followed by
brilliant blue G-colloidal stain concentrate (Sigma) and
protein bands were excised using a razor blade. After
destaining with 100 uL of 50% ACN, 50 mM NH4HCO3/
50% ACN and 10 mM NH4HCO3/50% ACN, the gel slices
were dried and incubated with 0.1 ug/uL trypsin
(Promega, Madison, WI) overnight at 37°C. Peptides
were extracted with 0.1% TFA/60% ACN, dried and re-sus-
pended in 0.5% TFA.
Protein Identification
After tryptic digest, samples were purified using reverse
phase C18 Zip Tips® (Millipore, Billerica, MA) according to
manufacturer's procedure and re-suspended in 0.1% for-
mic acid in water prior to LC-MS/MS analysis. Protein
identification was performed as described previously
(Rozek et al 2007) using ESI-LC-MS/MS system (LTQ-
Orbitrap, Thermo Scientific, Inc., San Jose, CA) in a nano-
spray configuration using a microcapillary RP-C18 column
(New Objectives, Woburn, MA) for fractionation. The
spectra were searched using Sequest™search engine in Bio-
Works 3.2 software (Thermo Scientific Inc., San Jose, CA)
using the following parameters: threshold for Dta genera-
tion = 10000, precursor ion mass tolerance = 1.4, peptide
tolerance = 2.00 and fragment ions tolerance = 1.00. Data-
base NCBI.fasta from http://ftp.ncbi.nih.gov was used
with two missed cleavage sites allowed and at least two
peptides were required for protein identification.
Western Blot Assays
1DE was performed on 7 HAD and 7 ND sera samples
using NuPAGE gel system (Invitrogen Corp., Carlsbad,
CA) in 4–12% gradient Bis-Tris gels under reducing con-
ditions. For Western blot analyses, 2 μg of serum protein
immunodepleted on an IgY column were loaded per lane.
The gel was transferred to Immun-Blot PVDF transfer
membrane using Ready Gel™Blotting Sandwiches (Bio-
Rad, Hercules, CA). After blocking with 5% rabbit serum
in PBST, the membrane was incubated with mouse anti-
gelsolin antibody (BD Transduction Laboratories, San
Jose, CA) followed by incubation with horseradish perox-
idase-conjugated goat anti-mouse IgG (Jackson Immu-
noResearch, West Grove, PA). A chemiluminescent signal
was detected using SuperSignal West Pico™Chemilumi-
nescent Substrate (Pierce, Rockford, IL) and signal was
recorded on Blue Lite X-ray film (ISCBioExpress, Kay-
sville, UT). Images were scanned into Adobe Photoshop,
adjusted using "Auto levels" and then analyzed using
ImageJ software available through NIH. Image was
inverted and a measurement box of exact same size was
used for each band analysis. All numbers were exported
into Microsoft Excel and measurements were normalized
between membranes.
Statistical Analysis
For SELDI-TOF data analysis, data from Biomarker Wizard
were exported for statistical analysis using SAS® software
9.1 (SAS Institute Inc., Cary, NC). Generalized estimating
equations (GEE) were used to identify peaks that showed
statistically significant differences in the distribution of
intensity scores among the various replicates of HIV-
infected individuals with or without HAD. The raw inten-Proteome Science 2009, 7:8 http://www.proteomesci.com/content/7/1/8
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sity values were found to be asymmetrical and trans-
formed prior to analysis using the arsinh function: Y =
log2(X + SQRT [X**2 + 1]), where 'X' is the observed
intensity. This transformation has been used previously to
stabilize intensity variance and make data more normally
distributed and it has the advantage over a log-transfor-
mation of being able to transform negative values [21].
After the GEE modeling, the Bonferroni correction was
used to address the issue of multiple testing.
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